Health secretary hints at ‘constructive’ talks over CF drugsHealth secretary Matt Hancock has offered hope to thousands of people in the UK who have been denied Share XHealth secretary hints at ‘constructive’ talks over CF drugshttps://pharmaphorum.com/news/health-secretary-hancock-hints-at-constructive-talks-vertex/
Market access roundup: Government grillings for Vertex and US pharmaIt was a month characterised by governments butting heads with pharma over pricing both in the UK and Share XMarket access roundup: Government grillings for Vertex and US pharmahttps://pharmaphorum.com/views-analysis-market-access/market-access-roundup-government-grillings-vertex-us-pharma-pricing/
Vertex CEO hints at ‘new ideas’ to bring Orkambi to UK patientsVertex CEO Jeffrey Leiden has offered an olive branch to negotiators in the UK that could see the Share XVertex CEO hints at ‘new ideas’ to bring Orkambi to UK patientshttps://pharmaphorum.com/news/vertex-ceo-hints-at-new-ideas-to-bring-orkambi-to-uk-patients/
UK politicians to grill Vertex CEO over CF price drug rowThe CEO of Vertex Pharmaceuticals is to give evidence before influential UK politicians on Thursday, who are investigating Share XUK politicians to grill Vertex CEO over CF price drug rowhttps://pharmaphorum.com/news/uk-politicians-to-grill-vertex-ceo-over-cf-price-drug-row/
Vertex calls for changes to NICE as CF drug profits soarVertex has revealed financial figures that are likely to go down well with investors, but not patients in Share XVertex calls for changes to NICE as CF drug profits soarhttps://pharmaphorum.com/news/vertex-calls-for-changes-to-nice-as-cf-drug-profits-soar/
Campaigners urge NHS to ignore patents on Vertex’s CF drugThe fight to get Vertex’s cystic fibrosis drug Orkambi available on England’s NHS continues, after pressure groups called Share XCampaigners urge NHS to ignore patents on Vertex’s CF drughttps://pharmaphorum.com/news/campaigners-urge-nhs-to-ignore-patents-on-vertexs-cf-drug/
Cystic fibrosis patients lobby Vertex to drop drug pricesHealthcare professionals and patient groups have written to Vertex’s CEO Jeffrey Leiden in a bid to resolve a Share XCystic fibrosis patients lobby Vertex to drop drug priceshttps://pharmaphorum.com/news/cystic-fibrosis-patients-lobby-vertex-to-drop-drug-prices/
Vertex licenses back CRISPR compounds from German MerckUS pharma Vertex has licensed back two gene editing compounds that can be used with CRISPR/Cas9 technology, from Share XVertex licenses back CRISPR compounds from German Merckhttps://pharmaphorum.com/news/vertex-licenses-back-crispr-compounds-from-german-merck/
Vertex sacks top exec, citing ‘personal behaviour’Vertex has fired its chief operating officer and acting chief financial officer, Ian Smith, citing unspecified “personal behaviour” Share XVertex sacks top exec, citing ‘personal behaviour’https://pharmaphorum.com/news/vertex-sacks-top-exec-citing-personal-behaviour/
